SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Brennan MF, Alektiar KM, Maki RG. Soft tissue sarcoma. In: Cancer: principles and practice of oncology. Philadelphia: Lippincott, Williams and Wilkens, 2001: 18411891.
  • 3
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472480.
  • 4
    Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br J Cancer. 1999; 79: 11581161.
  • 5
    Arthur G, Bittman R. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta. 1998; 1390: 85102.
  • 6
    Maly K, Uberall F, Schubert C, et al. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des. 1995; 10: 411425.
  • 7
    De Siervi A, Marinissen M, Diggs J, Wang XF, Pages G, Senderowicz A. Transcriptional activation of p21waf1/cip1 by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21waf1/cip1 promotor by Sp1. Cancer Res. 2004; 64: 743750.
  • 8
    Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti-Cancer Drugs. 2003; 14: 167173.
  • 9
    Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003; 2: 10931103.
  • 10
    Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer. 2002; 38: 16151621.
  • 11
    Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004; 10: 74507456.
  • 12
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 13
    Woo EW, Messmann R, Sausville EA, Figg WD. Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2001; 759: 247257.
  • 14
    Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials. 2001; 22: 117125.
  • 15
    Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002; 94: 32253229.
  • 16
    Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics. 1987; 43: 8193.
  • 17
    Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    La Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus rh GM-CSF in advanced soft tissue sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol. 2000; 18: 26762684.
  • 19
    Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer. 2002; 38: 543549.
  • 20
    La Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol. 2005; 23: 576584.